Vyvanse Adolescent (12 to 17) Dosing: Complete Clinical Guide

What Is the FDA-Approved Dosing Schedule for Vyvanse in Adolescents?

The FDA-approved starting dose of Vyvanse for adolescents aged 12 to 17 is 30 mg orally once every morning. Clinicians may increase the dose by 10 mg or 20 mg at weekly intervals based on therapeutic response and tolerability. The ceiling is 70 mg per day. No evidence supports that doses above 70 mg confer additional clinical benefit in this age group [1].

Starting Dose and First Two Weeks

Most adolescents begin at 30 mg. Some prescribers start sensitive patients at 20 mg off-label to reduce early side effects such as appetite suppression and insomnia, then move to 30 mg after one week if tolerated. The FDA label does not list 20 mg as a starting option for adolescents, so this approach requires documented clinical reasoning [1].

Families should give the first dose on a school morning so that any side effects occur when the patient is observable. Food does not affect the extent of lisdexamfetamine absorption, though a high-fat meal may delay peak plasma concentration by approximately one hour [1].

Titration: Weekly Steps to Target Dose

After the first week at 30 mg, the prescriber evaluates ADHD symptom control using a validated rating scale such as the ADHD Rating Scale-5 (ADHD-RS-5) or the Conners 3. If symptoms remain above target, the dose increases to 40 mg, 50 mg, 60 mg, or 70 mg in successive weekly steps [2].

Jumping two steps (20 mg) at once is allowable under the label when symptom burden is high and tolerability is good. Slower titration, 10 mg per week, suits patients who are underweight, have anxiety comorbidity, or show cardiovascular sensitivity [1].

The Wigal et al. Analog classroom study (N=129, ages 6 to 17) confirmed symptom reduction persisting 12 to 13 hours post-dose, supporting once-daily morning administration without supplemental afternoon doses [3].

Maintenance and Maximum Dose

Once the patient reaches adequate control, the maintenance dose stays fixed unless weight, growth, or clinical status changes. Annual re-evaluation of the continued need for stimulant therapy is standard practice per the American Academy of Pediatrics 2019 ADHD guidelines [4]. The maximum dose of 70 mg per day applies regardless of body weight; weight-based dosing calculations are not used with lisdexamfetamine [1].

How Does Lisdexamfetamine Work in Adolescents?

Lisdexamfetamine is a prodrug. After oral ingestion, intestinal and red-blood-cell enzymes cleave it to d-amphetamine and l-lysine. Only d-amphetamine is pharmacologically active. This conversion mechanism blunts the sharp concentration spike seen with immediate-release amphetamine salts, which may reduce abuse potential and cardiovascular stress [5].

Pharmacokinetics Relevant to Teen Patients

Peak plasma d-amphetamine concentration (Tmax) occurs approximately 3.8 hours after a 70 mg lisdexamfetamine dose in adults; adolescent data are similar [1]. The half-life of d-amphetamine averages about 10 to 13 hours, which accounts for the observed 12 to 14 hour duration of action seen in school-day studies [3].

Because lisdexamfetamine itself has a very short half-life (less than one hour), it cannot be extracted from a capsule and insufflated to produce a faster effect, unlike some other amphetamine formulations [5]. The FDA cited this property in its scheduling review [6].

Receptor Activity and Symptom Profile

D-amphetamine increases synaptic dopamine and norepinephrine by promoting efflux through the dopamine transporter and norepinephrine transporter, and by inhibiting monoamine oxidase. In adolescents with ADHD, this mechanism improves sustained attention, impulse control, and working memory [7].

A 2021 Cochrane review of amphetamines for ADHD in children and adolescents (k=21 trials, N=3,315) rated the evidence for short-term symptom improvement as moderate quality, with a standardized mean difference of 0.77 (95% CI 0.62 to 0.91) favoring amphetamine over placebo [8].

What Doses Are Used at Each Age and Weight Range?

Weight does not determine the lisdexamfetamine dose directly, but low body weight increases exposure per kilogram and therefore raises the risk of side effects. The FDA label does not provide weight-based dosing tables for adolescents [1].

Practical Weight Considerations

Adolescents weighing less than 40 kg often show adequate symptom control at lower doses (30 to 50 mg) and are more susceptible to appetite suppression and growth effects. A prescriber managing a 35 kg, 13-year-old may find that 40 mg provides sufficient control and keep the dose there rather than pushing toward 70 mg [9].

Adolescents weighing over 70 kg who are physically larger may require doses toward the upper range (60 to 70 mg) for effect, though the evidence base does not confirm a linear weight-dose relationship. Clinical response, not weight arithmetic, guides the decision [1].

Dose Forms Available

Vyvanse is available as:

• Capsules: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg
• Chewable tablets: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg

Capsules may be opened and the contents dissolved in water, yogurt, or orange juice for patients who cannot swallow capsules. The entire mixture must be consumed immediately [1]. Chewable tablets provide the same options for adolescents who prefer not to swallow capsules.

What Are the Monitoring Requirements During Adolescent Treatment?

Stimulant therapy in adolescents requires systematic monitoring at every visit. Growth velocity, cardiovascular parameters, psychiatric symptoms, and substance use history all need documentation [4].

Growth Velocity and Height Monitoring

Stimulants reduce appetite and may slow growth velocity in some adolescents. The FDA label includes a warning that height and weight should be tracked throughout treatment [1]. A 2014 MTA Cooperative Group follow-up (N=579) found that children treated with stimulants for 3 years were on average 2.0 cm shorter and 2.7 kg lighter than unmedicated peers, though the effect appeared to plateau [10].

Clinicians plot height and weight on CDC growth charts at each visit. If a patient crosses two major percentile lines downward over 6 months, a drug holiday or dose reduction discussion is warranted [4].

Cardiovascular Monitoring

Lisdexamfetamine raises heart rate and blood pressure modestly. In clinical trials, mean increases were approximately 2 to 4 beats per minute for heart rate and 1 to 3 mmHg for systolic blood pressure [1]. The American Heart Association recommends an electrocardiogram before stimulant initiation in any patient with a personal or family history of structural heart disease, arrhythmia, or unexplained syncope [11].

Resting heart rate and blood pressure should be recorded at baseline and at every follow-up visit. If a teen develops persistent resting tachycardia above 100 bpm or hypertension above the 95th percentile for age and height, the prescriber should reassess the dose [11].

Psychiatric and Behavioral Monitoring

Stimulants may precipitate or worsen anxiety, irritability, or mood lability in adolescents. The FDA label carries a warning about new or worsening psychiatric symptoms, including hallucinations in patients without prior psychiatric history [1]. Screening with the Pediatric Symptom Checklist or a clinician-administered mood assessment at each visit helps detect emerging problems early [4].

Suicidal ideation screening (using the Columbia Suicide Severity Rating Scale or equivalent) is part of good practice when managing any psychotropic medication in adolescents [12].

Substance Use Screening

Schedule II stimulants carry diversion risk. Clinicians should screen for substance use at baseline and annually using a validated tool such as CRAFFT. Prescriptions for adolescents should ideally involve parents or guardians in the dispensing and administration process, and pill counts or pharmacy monitoring programs may be appropriate in higher-risk cases [13].

How Does Vyvanse Compare to Other Stimulants in Adolescents?

Vyvanse is one of several first-line stimulant options for adolescent ADHD. Head-to-head data in this specific age group are limited, but available comparative evidence informs clinical choice.

Vyvanse vs. Adderall XR

Adderall XR (mixed amphetamine salts extended-release) has a similar mechanism but uses a bead-based dual-release system rather than prodrug conversion. Both deliver d-amphetamine as the primary active moiety. A 2016 crossover study (N=32, ages 13 to 17) found comparable ADHD-RS-5 improvements with Vyvanse 50 to 70 mg and Adderall XR 20 to 30 mg over 4 weeks, with similar side-effect profiles [14].

Vyvanse's prodrug design means abuse by insufflation or rapid oral escalation is pharmacokinetically limited. For adolescents in households with known diversion risk, this property may tip the prescribing decision toward lisdexamfetamine [5].

Vyvanse vs. Concerta

Concerta (methylphenidate extended-release) works by a different mechanism, inhibiting dopamine and norepinephrine reuptake rather than promoting efflux. It is often preferred when amphetamines cause excessive side effects. The 2021 Cochrane review noted that amphetamines produced slightly larger effect sizes than methylphenidate for symptom reduction (SMD 0.77 vs. 0.57), though direct head-to-head trials in adolescents are few [8].

Vyvanse vs. Strattera

Strattera (atomoxetine) is a non-stimulant alternative. It does not have abuse potential and does not require Schedule II prescribing restrictions. Effect sizes are smaller than stimulants (SMD approximately 0.45 in adolescents) and onset of full effect takes 4 to 6 weeks [15]. Strattera suits adolescents who have not responded to or cannot tolerate stimulants, or those with active substance use disorders where prescribing a Schedule II drug poses unacceptable risk [4].

What Side Effects Should Adolescents and Parents Expect?

Side effects of lisdexamfetamine in adolescents are dose-dependent and generally manageable with timing adjustments or dose reductions.

Appetite and Weight

Appetite suppression is the most common side effect, reported in 27 to 39% of adolescent trial participants at doses of 30 to 70 mg [1]. Practical management includes eating breakfast before the morning dose, offering a calorie-dense afternoon snack after the peak drug effect fades (around 3 to 4 pm), and scheduling a larger evening meal.

If weight loss exceeds 5% of baseline body weight over 4 weeks, the prescriber should consider a lower dose or a planned drug holiday during summer break [4].

Sleep

Insomnia occurs in approximately 11 to 19% of adolescents taking Vyvanse [1]. Taking the dose before 8 am reduces the likelihood of sleep-onset delay. Melatonin 0.5 to 3 mg at bedtime may help sleep onset and has a favorable safety profile in adolescents, though its use in this context is off-label [16].

Cardiovascular Effects

As noted above, modest heart rate and blood pressure increases are expected. Clinically significant cardiovascular events are rare but require prompt evaluation. Chest pain, palpitations, or dyspnea during stimulant therapy warrant immediate cardiac assessment [11].

Emotional Side Effects

Some adolescents experience irritability, emotional blunting, or dysphoria, particularly as the dose wears off in the late afternoon. This "rebound" phenomenon may respond to a small dose reduction or, in some cases, a low-dose immediate-release amphetamine supplement in the late afternoon, though supplemental dosing is off-label and requires careful justification [4].

Special Populations Within the Adolescent Age Group

Adolescents With Comorbid Anxiety

Anxiety disorders co-occur in approximately 25 to 50% of adolescents with ADHD [17]. Stimulants may worsen anxiety symptoms in some patients. Starting at the lowest available dose (20 mg off-label, or 30 mg per label) and titrating slowly gives the clinician time to distinguish ADHD-driven anxiety from stimulant-induced anxiety. If anxiety worsens beyond a manageable level at 30 to 40 mg, a non-stimulant or combined approach may be preferable [4].

Adolescents With Tics

The historical concern that stimulants worsen tics has been revisited. A 2002 controlled trial (TOSS study, N=136) found that methylphenidate did not worsen tics significantly compared to placebo, and limited data support a similar conclusion for amphetamines [18]. Current guidelines permit stimulant use in adolescents with comorbid tic disorders, with careful monitoring [4].

Adolescents With Low Body Weight or Eating Disorders

Appetite suppression makes lisdexamfetamine a high-risk choice for adolescents with anorexia nervosa or other restrictive eating disorders. A careful risk-benefit discussion with the patient and family, including monitoring of weight and caloric intake, is required before prescribing [1].

Transitioning to Adult Dosing at Age 18

At age 18, adolescent patients transitioning to adult care can continue at their established effective dose. The adult label for ADHD mirrors the adolescent label: 30 mg starting dose, titration to a maximum of 70 mg per day [1]. No dose adjustment is needed purely on the basis of turning 18.

How Long Does Vyvanse Treatment Last in Adolescents?

Duration of treatment is individualized. The AAP recommends re-evaluating the continued need for stimulant medication at least annually [4]. Some adolescents with ADHD continue to meet criteria throughout adulthood; others show sufficient maturation of prefrontal control by late adolescence that medication is no longer needed.

Drug holidays, typically during summer months when academic demands are lower, may allow assessment of whether medication remains necessary and can partially offset growth-velocity effects. Planned holidays should be discussed with patients and documented, not assumed by patients independently [4].

A 12-month open-label extension of the key lisdexamfetamine adolescent trial showed sustained ADHD symptom control with no new safety signals emerging beyond what was seen in the shorter-term phase [3]. The prescribing clinician should document ongoing benefit at each annual review using a validated rating scale score, not solely parental or patient report.

What Should Families Know Before Starting Vyvanse?

Families should understand the expected timeline: symptom improvement typically appears within the first two weeks at an effective dose, though titration to that dose may take four to eight weeks. The "right dose" is the lowest dose that provides meaningful symptom improvement without intolerable side effects.

Prescription logistics matter. Because Vyvanse is Schedule II, prescriptions cannot be called in by phone in most US states; paper or electronic prescriptions with the appropriate state controls are required. Most pharmacies stock all dose strengths, but 10 mg and 20 mg capsules are sometimes in shorter supply; confirming availability before the appointment saves time [6].

Patients and families should store Vyvanse in a locked cabinet, given diversion risk among adolescent social networks [13]. The DEA reports that prescription stimulant misuse among 12th graders was approximately 4.5% in 2022, down from a peak of 7.6% in 2012, but still a meaningful public health concern [19].

The FDA Medication Guide for Vyvanse must be provided to the patient and reviewed at initiation and with each new prescription [1].